Hamilton Thorne Ltd.
HTL.V
Toronto Stock Exchange Ventures1.45
CAD
+0.06
- -
Hamilton Thorne Ltd.
HTL.V
(Toronto Stock Exchange Ventures)
Recent
price
1.45
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Hamilton Thorne Ltd. (HTL.V), now operating as part of Nexpring Health following its take-private acquisition by Astorg in late 2024, provides precision instruments, consumables, software, and services to the assisted reproductive technologies (ART), research, and cell biology markets. The company develops, manufactures, and distributes core products including sperm analyzers and computer-assisted sperm analysis (CASA) systems such as those from Microptic; precision laser systems like Lykos and HT lasers for embryo biopsy and micromanipulation; imaging systems; laboratory equipment comprising IVF workstations (e.g., Javica from IVFtech), incubators, freezers, air purifiers, and microscope stage warmers from brands like Planer and Tek-Event; consumables such as embryo culture media, micropipettes, specialty needles, catheters (e.g., Guardia embryo transfer catheters and Cook pipettes), and ovum pickup devices from Gynemed and Gynetics; and services including sperm assays (Sperm Motility Index, Sperm Penetration), endotoxin testing, mouse embryo supply, and technician training. These offerings support the full IVF workflow—from semen analysis and ovum pickup through fertilization, embryo development, transfer, and vitrification—for fertility clinics, hospitals, pharmaceutical firms, biotechnology companies, academic institutions, and animal research facilities in approximately 100 countries. In recent developments, Hamilton Thorne entered into a definitive agreement in July 2024 to be acquired by an Astorg-managed vehicle for CAD 2.25 per share, a transaction that completed on November 30, 2024, resulting in delisting from the TSX Venture Exchange and its integration with Cook Medical's Reproductive Health business to form a combined ART platform; this was followed by the unveiling of Nexpring Health as the new unified brand in early 2025. Concurrently, an affiliate signed a definitive agreement in January 2025 to acquire FUJIFILM Irvine Scientific's ART and cytogenetics medical media business unit, anticipated to close on April 1, 2025, further expanding its media and consumables portfolio. The company maintains direct sales operations in the United States, Germany, France, Australia, Denmark, Belgium, Spain, and the United Kingdom, complemented by a global distributor network. Founded through a reverse asset acquisition in 2009 and tracing operational roots to Hamilton Thorne Inc. established in the 1980s, the company is headquartered in Beverly, Massachusetts, with key subsidiaries including Gynemed & Co. GmbH (acquired 2017), Planer Ltd. (2019), Tek-Event (2021), IVFtech ApS (2021), Microptic S.L. (2022), and Gynetics (2023). Nexpring Health, under Astorg's ownership, continues to serve as a comprehensive ART solutions provider across the Americas, Europe, Asia-Pacific, Middle East, and Africa.